Abemaciclib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1365 publications
Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.
Journal: Future oncology (London, England)
Published: June 22, 2026
LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma.
Journal: Science advances
Published: June 12, 2026
Real-world data on patients with HR+, HER2- early breast cancer prescribed with abemaciclib adjuvant therapy for 2 years in Japan.
Journal: Future oncology (London, England)
Published: June 08, 2026
Non-Genetic Mechanisms of Fractional Resistance to Abemaciclib in Dedifferentiated Liposarcoma.
Journal: bioRxiv : the preprint server for biology
Published: June 05, 2026
Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey.
Journal: Clinical journal of oncology nursing
Published: June 02, 2026
Abemaciclib Inhibits Retinoblastoma Tumor Growth by Targeting CDK1/2.
Journal: Investigative ophthalmology & visual science
Published: May 29, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 22, 2026
Establishment of PDX/PDXO models to evaluate the antitumor efficacy and mechanism of Abemaciclib in gastric-type cervical cancer.
Journal: Histology and histopathology
Published: May 22, 2026
Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communication.
Journal: Future oncology (London, England)
Published: May 22, 2026
CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins.
Journal: bioRxiv : the preprint server for biology
Published: May 04, 2026
Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.
Journal: Journal of clinical medicine
Published: April 16, 2026
Last Updated: 06/30/2026